Pemphigus: A treatment update

References

• Uzun S, Durdu M, Akman A, et al. Pemphigus in the Mediterranean region of Turkey: A study of 148 cases. Int J Dermatol 2006; 45: 523–528
   PubMed Web of Science ®Google Scholar
• Simon DG, Krutchkoff D, Kaslow RA, et al. Pemphigus in Hartford County Connecticut, from 1972 to 1977. Arch Dermatol 1980; 116: 1035–1037
   PubMedGoogle Scholar
• Pisant S, Sharav Y, Kaufman E, et al. Pemphius vulgaris: Incidence in Jews of different ethnic groups, according to age, sex, and initial lesion. Oral Surg Oral Med Oral Pathol 1974; 58: 382–387
   Google Scholar
• Krain L. Epidemiologic and survival characteristics of 59 patients, 1955-1973. Arch Dermatol 1974; 110: 862–865
   PubMedGoogle Scholar
• Aboobaker J, Morar N, Ramdial PK, et al. Pemphigus in South Africa. Int J Dermatol 2001; 40: 115–119
   PubMed Web of Science ®Google Scholar
• Mahe A, Flageul B, Cisse I, et al. Pemphigus in Mali: A study of 30 cases. Br J Dermatol 1996; 134: 114–119
   PubMed Web of Science ®Google Scholar
• Hans-Filho G, dos Santos V, Katayama JH, et al. An active focus of high prevalence of fogo selvagem on an amerindian reservation in Brazil. J Invest Dermatol 1996; 107: 68–75, Cooperative Group on Fogo Selvagem Research
   PubMedGoogle Scholar
• Warren SJ, Lin MS, Giudice GJ, et al. The prevalence of antibodies against desmoglein 1 in endemic pemphigus foliaceus in Brazil. N Engl J Med 2000; 343: 23–30, Cooperative Group on Fogo Selvagem Research
   PubMed Web of Science ®Google Scholar
• Kallel Sellami M, Ben Ayed M, Mouquet H, et al. Anti-desmoglein 1 antibodies in Tunisian healthy subjects: Arguments for the role of environmental factors in the occurrence of Tunisian pemphigus foliaceus. Clin Exp Immunol 2004; 137: 195–200
   PubMed Web of Science ®Google Scholar
• Bastuji-Garin S, Souissi R, Blum L, et al. Comparative epidemiology of pemphigus in Tunisia and France: Unusual incidence of pemphigus foliaceus in young Tunisian women. J Invest Dermatol 1995; 104: 302–305
   PubMed Web of Science ®Google Scholar
• Abreu-Velez AM, Hashimoto T, Bollag WB, et al. A unique form of endemic pemphigus in northern Colombia. J Am Acad Dermatol 2003; 49: 599–608
   PubMed Web of Science ®Google Scholar
• Abreu-Velez AM, Beutner EH, Montoya F, et al. Analyses of autoantigens in a new form of endemic pemphigus foliaceus in Colombia. J Am Acad Dermatol 2003; 49: 609–614
   PubMed Web of Science ®Google Scholar
• Loiseau P, Lecleach L, Prost C, et al. HLA class II polymorphism contributes to specify desmoglein derived peptides in pemphigus vulgaris and pemphigus foliaceus. J Autoimmun 2000; 15: 67–73
   PubMed Web of Science ®Google Scholar
• Tron F, Gilbert D, Mouquet H, et al. Genetic factors in pemphigus. J Autoimmun 2005; 24: 319–328
   PubMed Web of Science ®Google Scholar
• Aoki V, Millikan RC, Rivitti EA, et al. Environmental risk factors in endemic pemphigus foliaceus (fogo selvagem). J Investig Dermatol Symp Proc 2004; 9: 34–40
   PubMed Web of Science ®Google Scholar
• Amagai M, Tsunoda K, Zillikens D, et al. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999; 40: 167–170
   PubMed Web of Science ®Google Scholar
• Nguyen VT, Lee TX, Ndoye A, et al. The pathophysiological significance of nondesmoglein targets of pemphigus autoimmunity. Development of antibodies against keratinocyte cholinergic receptors in patients with pemphigus vulgaris and pemphigus foliaceus. Arch Dermatol 1998; 134: 971–980
   PubMedGoogle Scholar
• Nguyen VT, Ndoye A, Shultz LD, et al. Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions. J Clin Invest 2000; 106: 1467–1479
   PubMed Web of Science ®Google Scholar
• Nguyen VT, Arredondo J, Chernyavsky AI, et al. Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists. Arch Dermatol 2004; 140: 327–334
   PubMed Web of Science ®Google Scholar
• Feliciani C, Toto P, Amerio P, et al. In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: Interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis. J Invest Dermatol 2000; 114: 71–77
   PubMed Web of Science ®Google Scholar
• Lopez-Robles E, Avalos-Diaz E, Vega-Memije E, et al. TNF alpha and IL-6 are mediators in the blistering process of pemphigus. Int J Dermatol 2001; 40: 185–188
   PubMed Web of Science ®Google Scholar
• Bystryn JC. Adjuvant therapy of pemphigus. Arch Dermatol 1984; 120: 941–951
   PubMedGoogle Scholar
• Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol 1996; 132: 203–212
   PubMed Web of Science ®Google Scholar
• Ratnam KV, Phay KL, Tan CK. Pemphigus therapy with oral prednisolone regimens. A 5-year study. Int J Dermatol 1990; 29: 363–367
   PubMed Web of Science ®Google Scholar
• Fernandes NC, Perez M. Treatment of pemphigus vulgaris and pemphigus foliaceus: Experience with 71 patients over a 20 year period. Rev Inst Med Trop Sao Paulo 2001; 43: 33–36
   PubMedGoogle Scholar
• Mentink LF, Mackenzie MW, Toth GG, et al. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. Arch Dermatol 2006; 142: 570–576
   PubMedGoogle Scholar
• Femiano F, Gombos F, Scully C. Pemphigus vulgaris with oral involvement: Evaluation of two different systemic corticosteroid therapeutic protocols. J Eur Acad Dermatol Venereol 2002; 16: 353–356
   PubMed Web of Science ®Google Scholar
• Mignogna MD, Lo Muzio L, Ruoppo E, et al. High-dose intravenous ’pulse’ methylprednisone in the treatment of severe oropharyngeal pemphigus: A pilot study. J Oral Pathol Med 2002; 31: 339–344
   PubMed Web of Science ®Google Scholar
• Toth GG, van de Meer JB, Jonkman MF. Dexamethasone pulse therapy in pemphigus. J Eur Acad Dermatol Venereol 2002; 16: 607–611
   PubMed Web of Science ®Google Scholar
• Werth VP. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol 1996; 132: 1435–1439
   PubMed Web of Science ®Google Scholar
• Chryssomallis F, Dimitriades A, Chaidemenos GC, et al. Steroid-pulse therapy in pemphigus vulgaris long term follow-up. Int J Dermatol 1995; 34: 438–442
   PubMed Web of Science ®Google Scholar
• Akhtar SJ, Hasan MU. Treatment of pemphigus: a local experience. J Pak Med Assoc 1998; 48: 300–304
   PubMedGoogle Scholar
• Aberer W, Wolff-Schreiner EC, Stingl G, et al. Azathioprine in the treatment of pemphigus vulgaris. A long-term follow-up. J Am Acad Dermatol 1987; 16: 527–533
   PubMed Web of Science ®Google Scholar
• Benoit Corven C, Carvalho P, Prost C, et al. [Treatment of pemphigus vulgaris by azathioprine and low doses of prednisone (Lever scheme)]. Ann Dermatol Venereol 2003; 130: 13–15
   PubMed Web of Science ®Google Scholar
• Mourellou O, Chaidemenos GC, Koussidou T, et al. The treatment of pemphigus vulgaris. Experience with 48 patients seen over an 11-year period. Br J Dermatol 1995; 133: 83–87
   PubMed Web of Science ®Google Scholar
• Mimouni D, Anhalt GJ, Cummins DL, et al. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol 2003; 139: 739–742
   PubMed Web of Science ®Google Scholar
• Powell AM, Albert S, Al Fares S, et al. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol 2003; 149: 138–145
   PubMed Web of Science ®Google Scholar
• Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol 1999; 135: 54–56
   PubMed Web of Science ®Google Scholar
• Chams-Davatchi C, Nonahal Azar R, Daneshpazooh M, et al. [Open trial of mycophenolate mofetil in the treatment of resistant pemphigus vulgaris]. Ann Dermatol Venereol 2002; 129: 23–25
   PubMed Web of Science ®Google Scholar
• Nousari HC, Anhalt GJ. The role of mycophenolate mofetil in the management of pemphigus. Arch Dermatol 1999; 135: 853–854
   PubMedGoogle Scholar
• Enk AH, Knop J. Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet 1997; 350–494
   PubMedGoogle Scholar
• Mashkilleyson N, Mashkilleyson AL. Mucous membrane manifestations of pemphigus vulgaris. A 25-year survey of 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate or heparin. Acta Derm Venereol 1988; 68: 413–421
   PubMed Web of Science ®Google Scholar
• Smith TJ, Bystryn JC. Methotrexate as an adjuvant treatment for pemphigus vulgaris. Arch Dermatol 1999; 135: 1275–1276
   PubMedGoogle Scholar
• Shah N, Green AR, Elgart GW, et al. The use of chlorambucil with prednisone in the treatment of pemphigus. J Am Acad Dermatol 2000; 42: 85–88
   PubMedGoogle Scholar
• Piamphongsant T. Treatment of pemphigus with corticosteroids and cyclophosphamide. J Dermatol 1979; 6: 359–363
   PubMedGoogle Scholar
• Fellner MJ, Katz JM, McCabe JB. Successful use of cyclophosphamide and prednisone for initial treatment of pemphigus vulgaris. Arch Dermatol 1978; 114: 889–894
   PubMedGoogle Scholar
• Cummins DL, Mimouni D, Anhalt GJ, et al. Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus. J Am Acad Dermatol 2003; 49: 276–280
   PubMed Web of Science ®Google Scholar
• Chrysomallis F, Ioannides D, Teknetzis A, et al. Treatment of oral pemphigus vulgaris. Int J Dermatol 1994; 33: 803–807
   PubMed Web of Science ®Google Scholar
• Sacchidanand S, Hiremath NC, Natraj HV, et al. Dexamethasone–cyclophosphamide pulse therapy for autoimmune-vesiculobullous disorders at Victoria hospital Bangalore. Dermatol Online J 2003; 9: 2
   PubMedGoogle Scholar
• Fleischli ME, Valek RH, Pandya AG. Pulse intravenous cyclophosphamide therapy in pemphigus. Arch Dermatol 1999; 135: 57–61
   PubMedGoogle Scholar
• Kaur S, Kanwar AJ. Dexamethasone–cyclophosphamide pulse therapy in pemphigus. Int J Dermatol 1990; 29: 371–374
   PubMed Web of Science ®Google Scholar
• Kanwar AJ, Kaur S, Thami GP. Long-term efficacy of dexamethasone–cyclophosphamide pulse therapy in pemphigus. Dermatology 2002; 204: 228–231
   PubMedGoogle Scholar
• Pasricha JS, Thanzama J, Khan UK. Intermittent high-dose dexamethasone–cyclophosphamide therapy for pemphigus. Br J Dermatol 1988; 119: 73–77
   PubMed Web of Science ®Google Scholar
• Pasricha JS, Khaitan BK, Raman RS, et al. Dexamethasone–cyclophosphamide pulse therapy for pemphigus. Int J Dermatol 1995; 34: 875–882
   PubMedGoogle Scholar
• Rose E, Wever S, Zilliken D, et al. Intravenous dexamethasone–cyclophosphamide pulse therapy in comparison with oral methylprednisolone–azathioprine therapy in patients with pemphigus: Results of a multicenter prospectively randomized study. Journal der Deutschen Dermatologischen Gesellschaft 2005; 3: 200–206
   PubMedGoogle Scholar
• Ioannides D, Chrysomallis F, Bystryn JC. Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol 2000; 136: 868–872
   PubMedGoogle Scholar
• Mobini N, Padilla T, Jr, Ahmed AR. Long-term remission in selected patients with pemphigus vulgaris treated with cyclosporine. J Am Acad Dermatol 1997; 36: 264–266
   PubMed Web of Science ®Google Scholar
• Werth VP, Fivenson D, Pandya A, et al. Randomized placebo-controlled clinical trial of dapsone as a glucocorticoid-sparing agent in maintainance phase pemphigus vulgaris. J Invest Dermatol 2005; 125: 1088
   Google Scholar
• Heaphy MR, Albrecht J, Werth VP. Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol 2005; 141: 699–702
   PubMedGoogle Scholar
• Basset N, Guillot B, Michel B, et al. Dapsone as initial treatment in superficial pemphigus. Report of nine cases. Arch Dermatol 1987; 123: 783–785
   PubMedGoogle Scholar
• Auad A, Auad T. Terpaeutica coadjuvante no tratamento do penfigo foliaceo sul-americano com auranofina. Estudo duplo-cego. An Bras Dermatol 1986; 61: 131–134
   Google Scholar
• Pandya AG, Dyke C. Treatment of pemphigus with gold. Arch Dermatol 1998; 134: 1104–1107
   PubMedGoogle Scholar
• Sutej PG, Jorizzo JL, White W. Intramuscular gold therapy for young patients with pemphigus vulgaris: A prospective, open, clinical study utilizing a dermatologist/rheumatologist team approach. J eur Dermatol Venereol 2006; 5: 222–228
   Google Scholar
• Poulin Y, Perry HO, Muller SA. Pemphigus vulgaris: Results of treatment with gold as a steroid-sparing agent in a series of thirteen patients. J Am Acad Dermatol 1984; 11: 851–857
   PubMed Web of Science ®Google Scholar
• Penneys NS, Eaglstein WH, Frost P. Management of pemphigus with gold compounds: A long-term follow-up report. Arch Dermatol 1976; 112: 185–187
   PubMedGoogle Scholar
• Iranzo R, Alsina M, Segura S, et al. Chrysotherapy of 13 patients with pemphigus vulgaris refractory to previous therapies. J Invest Dermatol 2005; 125: 1090
   Google Scholar
• Calebotta A, Saenz AM, Gonzalez F, et al. Pemphigus vulgaris: Benefits of tetracycline as adjuvant therapy in a series of thirteen patients. Int J Dermatol 1999; 38: 217–221
   PubMedGoogle Scholar
• Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: A review of 13 cases. J Am Acad Dermatol 1993; 28: 998–1000
   PubMed Web of Science ®Google Scholar
• Gaspar ZS, Walkden V, Wojnarowska F. Minocycline is a useful adjuvant therapy for pemphigus. Australas J Dermatol 1996; 37: 93–95
   PubMedGoogle Scholar
• Alpsoy E, Yilmaz E, Basaran E, et al. Is the combination of tetracycline and nicotinamide therapy alone effective in pemphigus?. Arch Dermatol 1995; 131: 1339–1340
   PubMedGoogle Scholar
• Guillaume JC, Roujeau JC, Morel P, et al. Controlled study of plasma exchange in pemphigus. Arch Dermatol 1988; 124: 1659–1663
   PubMedGoogle Scholar
• Sondergaard K, Carstens J, Zachariae H. The steroid-sparing effect of long-term plasmapheresis in pemphigus: An update. Ther Apher 1997; 1: 155–158
   PubMedGoogle Scholar
• Roujeau JC, Andre C, Joneau Fabre M, et al. Plasma exchange in pemphigus. Uncontrolled study of ten patients. Arch Dermatol 1983; 119: 215–221
   PubMedGoogle Scholar
• Ruocco V, Astarita C, Pisani M. Plasmapheresis as an alternative or adjunctive therapy in problem cases of pemphigus. Dermatologica 1984; 168: 219–223
   PubMedGoogle Scholar
• Blaszczyk M, Chorzelski TP, Jablonska S, et al. Indications for future studies on the treatment of pemphigus with plasmapheresis. Arch Dermatol 1989; 125: 843–844
   PubMedGoogle Scholar
• Tan-Lim R, Bystryn JC. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol 1990; 22: 35–40
   PubMed Web of Science ®Google Scholar
• Turner MS, Sutton D, Sauder DN. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2000; 43: 1058–1064
   PubMed Web of Science ®Google Scholar
• Arin MJ, Engert A, Krieg T, et al. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 2005; 153: 620–625
   PubMed Web of Science ®Google Scholar
• Cianchini G, Ruffelli M, Corona R, et al. Rituximab in the treatment of severe pemphigus vulgaris: A report of five cases. J Invest Dermatol 2005; 125: 1089
   Google Scholar
• Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol 2004; 51: 817–819
   PubMed Web of Science ®Google Scholar
• Dupuy A, Viguier M, Bedane C, et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 2004; 140: 91–96
   PubMed Web of Science ®Google Scholar
• Jacobi A, Shuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol 2005; 153: 448–449
   PubMed Web of Science ®Google Scholar
• Pardo J, Mercader P, Mahiques L, et al. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol 2005; 153: 222–223
   PubMed Web of Science ®Google Scholar
• Lin M, Hsu C, Lee J. Successful treatment of the recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol 2005; 141: 680–682
   PubMed Web of Science ®Google Scholar
• Berookhim B, Fischer HD, Weinberg JM. Treatment of recalcitrant pemphigus vulgaris with tumor necrosis factor alpha antagonist etanercept. Cutis 2004; 74: 245–247
   PubMed Web of Science ®Google Scholar
• Howell SM, Bessinger GT, Altman CE, et al. Rapid response of IgA pemphigus of the subcorneal pustular dermatosis subtype tp treatment with adalimumab and mycophenolate mofetil. J Am Acad Dermatol 2005; 53: 541–543
   PubMed Web of Science ®Google Scholar
• Zia S, Ndoye A, Lee TX, et al. Receptor-mediated inhibition of keratinocyte migration by nicotine involves modulations of calcium influx and intracellular concentration. J Pharmacol Exp Ther 2000; 293: 973–981
   PubMed Web of Science ®Google Scholar
• Nguyen VT, Arredondo J, Chernyavsky AI, et al. Keratinocyte acetylcholine receptors regulate cell adhesion. Life Sci 2003; 72: 2081–2085
   PubMedGoogle Scholar
• Grando SA, Horton RM, Mauro TM, et al. Activation of keratinocyte nicotinic cholinergic receptors stimulates calcium influx and enhances cell differentiation. J Invest Dermatol 1996; 107: 412–418
   PubMed Web of Science ®Google Scholar
• Grando SA, Dahl MV. Activation of keratinocyte muscarinic acetylcholine receptors reverses pemphigus acantholysis. J Eur Acad Dermatol Venereol 1993; 2: 72–86
   Google Scholar
• Nguyen VT, Ndoye A, Grando SA. Novel human alpha9 acetylcholine receptor regulating keratinocyte adhesion is targeted by pemphigus vulgaris autoimmunity. Am J Pathol 2000; 157: 1377–1391
   PubMed Web of Science ®Google Scholar
• Nguyen VT, Ndoye A, Grando SA. Pemphigus vulgaris antibody identifies pemphaxin. A novel keratinocyte annexin-like molecule binding acetylcholine. J Biol Chem 2000; 275: 29466–29476
   PubMed Web of Science ®Google Scholar
• Grando SA. New approaches to the treatment of pemphigus. J Investig Dermatol Symp Proc 2004; 9: 84–91
   PubMedGoogle Scholar
• Iraji F, Yoosefi A. Healing effect of pilocarpine gel 4% on skin lesions of pemphigus vulgaris. Int J Dermatol 2006; 45: 743–746
   PubMed Web of Science ®Google Scholar
• Werth VP, Strober B, Connolly MK, et al. An open-label phase I clinical study to assess the safety of PI-0824 in patients with pemphigus vulgaris. J Invest Dermatol 2005; 125: A5:#930
   Google Scholar
• Anhalt GJ, Werth VP, Strober B, et al. An open-label phase I clinical study to assess the safety of PI-0824 in patients with pemphigus vulgaris. J Invest Dermatol 2005; 125: 1088
   Web of Science ®Google Scholar